Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
New SelectScience eBook helps scientists choose the best cell imaging technology
A new cell imaging technology guide has been launched by leading independent science publisher SelectScience® to help scientists find the best equipment for their applications.
Interim Report 1 2019/20
Interim Report 1 (2019-05-01 – 2019-07-31) from Phase Holographic Imaging.
US National Institutes of Health intends to purchase HoloMonitor
The US National Institute of Aging intends to purchase a HoloMonitor instrument from Phase Holographic Imaging. The National Institute of Aging is part of the National Institutes of Health (NIH), a government agency to promote medical research.
Minor insider divestment
PHI Board member Jan Richardsson recently divested 5 328 shares in the company. “The reason for the sale is that I needed to balance an option loss linked to a previous employment”, comments Richardsson.
A study on Adipocyte Migration based on HoloMonitor single-cell level results
In yet another publication scientists report on how HoloMonitor was used to study cell motility and migration for deeper understanding of cell biological processes.
Correction regarding the publication date of coming interim report
Year-end Report 2018/19
February – April 2019 Net sales 1 361 (2 180) KSEK Operating result -4 953 ( -1 955) KSEK Net result -6 350 (-3 820) KSEK Earnings per share -0.46 (-0.33) SEK May 2018 – April 2019 Net sales 4 601 (4 449) KSEK Operating result -17 424 (-8 393) KSEK Net result -23 050 …
Several researchers report on the use of HoloMonitor in the fight against severe brain cancers
Understanding of how different treatment options affect cell motility and migration is thus essential when exploring the effects of new treatment options in the fight against cancer.
PHI receives 18 MSEK through share options
On June 13, 2019, the exercise period of the TO 2 share options in Phase Holographic Imaging (“PHI”) ended. 632 520 (97.6 %) of the 648 338 outstanding options were exercised. PHI will thus receive approx. 17.8 MSEK before issuing expenses, which are expected to amount to approx. 0.8 MSEK.
PHI and leading supplier of cell analysis instrumentation sign agreement
Phase Holographic Imaging (PHI) and a major publicly traded international supplier of laboratory equipment and cell analysis instrumentation have entered an agreement aiming to determine the scope and nature of a future partnership. The agreement is a result of discussions between the company management teams, over an extended period time.